GSK Expands its Vaccine Presence in China - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GSK Expands its Vaccine Presence in China


ePT--the Electronic Newsletter of Pharmaceutical Technology

GlaxoSmithKline (GSK) has entered into an agreement to purchase Shenzhen Neptunus’ stake in a previously formed joint venture between the companies involved in the development and manufacture of influenza vaccines in China, Hong Kong, and Macau. GSK will pay Shenzhen Neptunus $39 million, after which GSK will be the sole owner of the joint venture company, Shenzhen GSK-Neptunus Biologicals (GSKNB).

GSKNB was established by GSK and Shenzhen Neptunus in June 2009, to develop and manufacture seasonal and pandemic influenza vaccines. The joint venture combined GSK’s adjuvant technology and expertise in vaccine development with Shenzhen Neptunus’ experience in the Chinese market. Under the terms of the original agreement, GSK was expected to purchase additional shares and obtain a majority equity interest in the company within two years. Subsequently, in August 2010, GSK increased its equity share in the joint company from 40% to 49%.

According to a statement from GSK, the decision to acquire all the outstanding interest in GSKNB reflects the company’s intention to further expand its vaccines presence in China, which it describes as a “fast growing emerging market.”

“GSK has licensed more vaccines in China than any other global manufacturer and has packaged more than 100 million vaccines at our Shanghai facility,” claimed John Lepore, vice-president and general manager of biologicals and corporate at GSK China, in the statement. “This announcement represents an expansion of GSK’s long-term commitment to vaccine supply, manufacturing and development in China.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here